Aiming to Strengthen Business in the Hematology and Non-Hematology Fields and to Transition Partially to a Direct Sales Structure.
Sysmex Corporation (HQ: Kobe, Japan; President and CEO: Hisashi Ietsugu) began the partial transition to a direct sales and support structure in Thailand on October 1, 2012, in a bid to reinforce its customer sales and support activities. The Company has commenced direct sales targeting private hospitals in the fields of hematology and non-hematology (urinalysis and clinical chemistry), as well as in the life sciences field.
As one of the six major ASEAN countries (which also include Indonesia, Malaysia, the Philippines and Singapore), Thailand is one of Southeast Asia’s leaders in terms of the percentage of government contributions to healthcare costs. Thailand’s in-vitro diagnostics market is expanding and is slated for further growth.
Sysmex conducts its sales and support activities in Thailand through Sysmex (Thailand) Co., Ltd., which was established in July 1999 as a joint venture with a local distributor. Converted to a wholly owned subsidiary in 2007, Sysmex Thailand promotes sales and support activities through local distributors. In addition to the mainstay hematology field, the company boasts a high share of the market in non-hematology fields such as hemostasis and urinalysis.
With the aim of reinforcing its sales and support activities, on October 1, 2012, Sysmex Thailand began conducting direct sales activities in select hematology and non-hematology fields to private hospitals in Central area including Bangkok. The company is targeting direct sales in hematology, as well as in such non-hematology fields as urinalysis, clinical chemistry and life sciences. The new structure will enable Sysmex Thailand to better respond to demand in the hematology field for upgrades to high-end instruments and systematization, as well as accompanying high-end support services. In addition to also buttressing its sales and support structure in non-hematology fields, the new structure is aimed at further bolstering customer satisfaction by enhancing scientific seminars—one of Sysmex’s strengths—and proposing proprietary Sysmex services such as SNCS*.
In Central area including Bangkok, the company will continue to conduct sales and support activities targeting public hospitals through distributors, as well as its activities in other regions. By leveraging the strengths of Sysmex and its distributors, Sysmex Thailand aims to continue supporting distributors and taking advantage of additional synergies.
Going forward, Sysmex aims to augment its sales and support structure and provide Sysmex-specific support services as it strives to contribute to the development of healthcare in Asia.
Overview of Sysmex Thailand
Name: Sysmex (Thailand) Co., Ltd.
Location: Bangkok, Thailand
Representative: Charoensuth Ngoenprasopsuk
Commencement of new operations: October 1, 2012
Capital: 200 million baht (approximately ¥500 million)
Capital supplied by: Sysmex Asia Pacific Pte Ltd., a wholly owned subsidiary of Sysmex Corporation
Lines of business:
Sales of in-vitro diagnostic instruments, reagents and laboratory information systems, and related after-sales support, in Central area including Bangkok
Support for the sales activities of local distributors in other regions
* An abbreviation for Sysmex Network Communication Systems, the SNCS® is an online support service that connects the Customer Support Center and customers’ products via an internet connection to provide real-time external quality control and scientific information and to monitor instrument conditions. A separate (paid) agreement is needed to use this service.